Dr. Eric Singhi sat down with CURE to interrupt down the newest findings from the section 3 FLAURA2 examine, offered on the World Convention on Lung Most cancers.
He defined how including chemotherapy to Tagrisso (osimertinib) improved total survival for sufferers with EGFR-positive lung most cancers by practically 10 months in contrast with Tagrisso alone.
Singhi, an assistant professor in each the Division of Common Oncology and Division of Thoracic/Head and Neck Medical Oncology, Division of Most cancers Drugs, The College of Texas MD Anderson Most cancers Middle, in Houston, additionally addressed how lengthy sufferers sometimes keep on chemotherapy on this setting and highlighted the significance of shared decision-making when contemplating therapy choices.
Transcript
Dr. Singhi, throughout the Presidential Symposium we heard necessary updates on EGFR-positive lung most cancers, significantly the FLAURA2 examine. Are you able to stroll us by way of the important thing findings and what they imply for sufferers?
Hiya from Barcelona! I am excited to be right here and to actually perceive the information that we are able to deliver residence for our sufferers, which is probably practice-changing. On Sunday’s Presidential Symposium right here on the World Convention on Lung Most cancers, we heard about updates for our sufferers with EGFR-positive illness. One of many research we have been ready for an replace on is the FLAURA2 examine.
It is a section 3 examine, so it had numerous sufferers who have been enrolled. Sufferers have been both randomized to the arm that had Tagrisso plus chemotherapy or Tagrisso alone. We have been ready to see not provided that one routine helps management the illness longer or helps shrink the illness higher, but additionally if the routine really helps sufferers stay longer.
What we discovered was that, sure, in the event you mix Tagrisso plus chemotherapy, it does enhance what we name total survival; in different phrases, how lengthy sufferers live. On common, we noticed a couple of 10-month enchancment in total survival if sufferers acquired chemotherapy with their Tagrisso. It is a actually necessary factor to think about and to have an knowledgeable, shared decision-making dialog together with your care workforce in the event you’re newly identified with EGFR-positive lung most cancers and are considering by way of your therapy choices.
One other actually good query that was answered, and doubtless a quite common query that many oncologists get of their clinic, is, “How lengthy do I’ve to be on the chemotherapy for? Can I simply be on the Tagrisso capsule sooner or later?” On common, within the examine, we noticed that sufferers have been on the chemotherapy portion for about 8.3 months. This provides you a bit perspective on how lengthy sufferers are in a position to tolerate chemotherapy, and most of them, sadly, need to discontinue the chemotherapy due to unwanted side effects. That was only a recap of the FLAURA2 examine.
Once more, there have been numerous actually thrilling research right here. Proceed to comply with alongside and take care.
Transcript has been edited for readability and conciseness.
For extra information on most cancers updates, analysis and training, don’t neglect to subscribe to CURE®’s newsletters right here.
